Ueda K, Obata K, Isogai K, Mori O, Ohshima S, Naruse K, Kuriyama M, Asaka H, Otani T, Fujnimoto Y
Nihon Hinyokika Gakkai Zasshi. 1990 Jan;81(1):110-5. doi: 10.5980/jpnjurol1989.81.110.
Registration of renal pelvic and ureteral tumor was done from 1980 through 1986, in the Tokai Urological Tumor Registry. Among the 404 cases of the carcinoma, 384 cases (210 renal pelvis, 174 ureter) were subjected to the present study. A total of 319 cases (83.1%) showed a complete cure, while 20 cases (5.2%) were considered as partial cure, and 45 cases (11.7%) were classified to progressive disease group. Chemotherapy was performed on 151 patients including systemic administration to 141 patients (33.9%) and 11 patients received combined intravesical instillation therapy. Irradiation was performed on 49 patients (12.8%). Degree of histological and morphological differentiation of renal pelvis and ureter tumor were studied in 341 cases of transitional cell carcinoma (88.8%); G0, 0.3%, G1, 12.9%, G2, 49.3%, Gx, 5.2%. Stage of the tumor were T1, 33.6%; T2, 12.5%; T3, 14.6%; T4, 13.3%; Tis, 0.3%; Tx, 24.7%. Five-year relative survival for carcinoma of the renal pelvis was 46.6%, and for the ureter it was 53.1%. Five-year survival according to histological differentiation of transitional cell carcinoma and according to the stage of the tumor were as follows; G1, 91.6%; G2, 58.5%; G3, 27.2%; Ta, 84.6%; T1. 74.2%; T2, 48.5%; T3, 24.1%, T4, 7.3%. The rate of survival was correlated with histological differentiation of the tumor cells. The survival was poor in cases who had the components of squamous cell carcinoma and/or adenocarcinoma. Overall survived case were 177, 122 patients died of cancer, 20 patients died of other causes than cancer, and 1 patient died from immediate surgical effect.(ABSTRACT TRUNCATED AT 250 WORDS)
1980年至1986年期间,在东海泌尿肿瘤登记处对肾盂和输尿管肿瘤进行了登记。在404例癌症病例中,384例(210例肾盂,174例输尿管)纳入本研究。共有319例(83.1%)显示完全治愈,20例(5.2%)被认为部分治愈,45例(11.7%)被归类为疾病进展组。151例患者接受了化疗,其中141例(33.9%)进行了全身给药,11例接受了膀胱内联合灌注治疗。49例患者(12.8%)接受了放疗。对341例移行细胞癌(88.8%)的肾盂和输尿管肿瘤的组织学和形态学分化程度进行了研究;G0为0.3%,G1为12.9%,G2为49.3%,Gx为5.2%。肿瘤分期为:T1为33.6%;T2为12.5%;T3为14.6%;T4为13.3%;Tis为0.3%;Tx为24.7%。肾盂癌的五年相对生存率为46.6%,输尿管癌为53.1%。根据移行细胞癌的组织学分化和肿瘤分期的五年生存率如下:G1为91.6%;G2为58.5%;G3为27.2%;Ta为84.6%;T1为74.2%;T2为48.5%;T3为24.1%,T4为7.3%。生存率与肿瘤细胞的组织学分化相关。伴有鳞状细胞癌和/或腺癌成分的病例生存率较差。总体存活病例177例,122例死于癌症,20例死于癌症以外的其他原因,1例死于手术直接影响。(摘要截选至250字)